SAFE Drugs Act of 2025
- Sponsor
- Rep. Yakym, Rudy [R-IN-2]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Dec 9, 2025
Bottom line
The bill aims to enhance FDA oversight of drug compounding to improve patient safety and prevent pharmacies from operating as unregulated drug manufacturers.
What it actually does
This bill amends the Federal Food, Drug, and Cosmetic Act to tighten regulations on compounding pharmacies and outsourcing facilities. It restricts traditional compounding pharmacies from producing more than 20 copies per month of commercially available drugs, mandates reporting for certain out-of-state compounding, and increases inspection frequency and registration requirements for large-scale outsourcing facilities. It also grants the Secretary of Health and Human Services discretion to set the base establishment fee for outsourcing facilities.
Proponents argue
Supporters argue this legislation is crucial for protecting public health by ensuring that compounded drugs meet appropriate safety and quality standards, especially when they closely mimic commercially available products or are produced at a large scale. They contend it closes loopholes that allow some facilities to operate with less scrutiny than traditional drug manufacturers, thereby preventing potential public health risks.
Opponents contend
Opponents might argue that the bill places undue administrative and financial burdens on compounding pharmacies and outsourcing facilities, which could limit patient access to essential customized medications. They may contend that the new restrictions could stifle innovation or increase costs for patients who rely on compounded drugs for specific medical needs not met by commercial products.
The bill is concise and its provisions are clearly articulated, allowing for a quick and thorough understanding by an informed reader.
Section 2, amending Section 503A(b) of the FD&C Act
Redefining 'Essentially a Copy of a Commercially Available Drug Product'
This section revises the definition of a compounded drug product that is 'essentially a copy' of a commercially available drug. It limits traditional compounding pharmacies from compounding such copies more than 20 times in a single month. The new definition specifies that a drug is 'essentially a copy' if it contains an active ingredient found in a commercially available product and there's no significant difference for an individual patient, as determined by the practitioner. It also clarifies what constitutes a 'commercially available drug product' by excluding discontinued products.
Supporters argue
Supporters argue this prevents compounding pharmacies from operating as de facto drug manufacturers without adhering to the stricter manufacturing standards (like Good Manufacturing Practices), thereby protecting patient safety and ensuring drug quality. It targets facilities that exploit a loophole to produce large volumes of nearly identical drugs, which should be subject to full FDA oversight.
Critics contend
Opponents might argue that this restricts patient access to necessary compounded medications, especially if a commercially available drug is on shortage, contains inactive ingredients causing patient allergies, or is not available in a suitable dosage form. They may claim it adds unnecessary burden to pharmacies providing essential, individualized patient services.
Tradeoffs
This provision balances patient access to customized compounded drugs against the need for robust regulatory oversight to ensure safety and quality, particularly for high-volume production that mimics commercial manufacturing.
Section 3, inserting new subsection (d) into Section 503A of the FD&C Act
New Reporting Requirement for Out-of-State Compounding
This section mandates that any pharmacy, facility, or physician that compounds a drug product containing an active ingredient found in a commercially available drug product more than 20 times in a single month for patients residing outside the state where compounding occurs, must submit an annual report to the Secretary. The report must identify the types of drugs compounded and the total number of times each type was compounded monthly. Hospital pharmacies compounding for their own patients are explicitly excluded from this requirement.
Section 4, amending Section 503B(b) and Section 510(g)(1) of the FD&C Act
Enhanced Inspections and Mandatory Registration for Large-Scale Outsourcing Facilities
This section introduces stricter inspection requirements for 'large-scale outsourcing facilities,' defined as facilities that compound any drug product more than 100 times in a single calendar year. These facilities must undergo an inspection prior to compounding any drug product for the first time and be reinspected at least biennially. Additionally, it removes the general exemption from registration requirements for all outsourcing facilities, meaning they must now register with the FDA. These changes apply six months after the bill's enactment.
Section 5, amending Section 744K(c)(1)(A)(i) of the FD&C Act
Adjusting Outsourcing Facility Base Establishment Fee
This section changes the fixed base establishment fee for outsourcing facilities from '$15,000' to 'a base amount deemed appropriate by the Secretary to fund activities to ensure the safety of compounded drug products.' This grants the Secretary of Health and Human Services (via the FDA) discretion to set the fee annually, rather than it being a static amount.